Royce & Associates LP Buys Shares of 37,225 Lantheus Holdings, Inc. (NASDAQ:LNTH)

Royce & Associates LP bought a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm bought 37,225 shares of the medical equipment provider’s stock, valued at approximately $3,330,000.

Other hedge funds have also recently bought and sold shares of the company. Geode Capital Management LLC increased its holdings in Lantheus by 2.0% in the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock valued at $184,798,000 after buying an additional 32,551 shares during the period. Massachusetts Financial Services Co. MA bought a new stake in shares of Lantheus during the 3rd quarter valued at approximately $25,955,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Lantheus by 47.7% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after purchasing an additional 3,772 shares during the last quarter. Empirical Asset Management LLC bought a new stake in shares of Lantheus during the 4th quarter valued at approximately $323,000. Finally, Focus Financial Network Inc. bought a new stake in shares of Lantheus during the 4th quarter valued at approximately $292,000. 99.06% of the stock is owned by institutional investors.

Lantheus Price Performance

NASDAQ:LNTH opened at $103.28 on Thursday. The company has a market cap of $7.07 billion, a PE ratio of 17.18 and a beta of 0.38. Lantheus Holdings, Inc. has a one year low of $57.78 and a one year high of $126.89. The firm’s 50 day simple moving average is $92.54 and its 200 day simple moving average is $96.68.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to analyst estimates of $376.61 million. Lantheus had a return on equity of 44.29% and a net margin of 28.57%. Equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insider Transactions at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. The trade was a 8.07 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director James H. Thrall sold 1,000 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $94.76, for a total transaction of $94,760.00. Following the transaction, the director now owns 33,207 shares in the company, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 64,109 shares of company stock worth $6,110,806. Company insiders own 1.50% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the topic of several research reports. Truist Financial lifted their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Finally, StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, Lantheus has an average rating of “Moderate Buy” and an average target price of $132.86.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.